Studies in myasthenia gravis. Pyridostigmine-C14 metabolism after thymectomy.
Pyridostigmine-carbon 14 (P-C14) excretion studies in myasthenia gravis patients who had had thymectomies failed to produce any significant difference from results observed in myasthenic patients who had not had thymectomies. Thus, change in P-C14 metabolism cannot help explain decreased anticholinesterase requirements and electromyographic changes observed in some patients following thymectomy.